Sign inJoin waitlistJoin the waitlist

Laura Holman

Program Director, Gyn Oncology Fellowshp Program · University of Oklahoma College of Medicine

Credentials: · · · · · · ·

History

Gyn Oncology Fellowshp Program · University of Oklahoma College of Medicine
Present
University of Oklahoma College of Medicine
Present

Linda K. Manning Fellowship in Ovarian Cancer Research MD Anderson Cancer Center
Obstetrics and Gynecology
Warren Alpert Medical School of Brown University in Providence
2015–2019
Gynecologic Oncology
University of Texas M D Anderson Cancer Center
2012–2015
Internal Medicine
Warren Alpert Medical School of Brown University in Providence
2007–2010
University of Illinois College of Medicine
2003–2007

Research

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology · 2024 · 148 citations
Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study
Journal of Clinical Oncology · 2020 · 142 citations
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study
Gynecologic Oncology · 2022 · 71 citations

Kathleen Moore
8 papers
Bradley Monk
6 papers
Karen Lu
6 papers
CA
Carol Aghajanian
5 papers
Charles Leath
5 papers
David Miller
5 papers
Floor Backes
5 papers
Jayanthi Lea
5 papers
Joan Walker
5 papers
Jyoti Mayadev
5 papers
Robert Mannel
5 papers
AO
Alexander Olawaiye
4 papers

Clinical trials

Bariatric Education for Women With Obesity and Endometrial Cancer
Principal investigator · Terminated
University of Oklahoma
2023–2025
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
Principal investigator · Active not recruiting · Early phase 1
University of Oklahoma
2019–2026
Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer
Principal investigator · Completed · Early phase 1
University of Oklahoma
2017–2020
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034